FIELD: medicine.
SUBSTANCE: present invention relates to medicine, in particular to biochemistry, pharmacology and clinical pharmacology, and can be used to study the mechanisms of myogenesis and evaluate the effect of medicinal substances on it. The present invention discloses a method for promoting myogenesis in a C2C12 cell line. To implement this method, C2C12 cells are incubated for 7 days with a differentiation nutrient medium containing 2% horse serum, L-glutamine at a concentration of 4 mm, penicillin at a concentration of 100 U/ml and streptomycin at a concentration of 100 mcg/ml with the addition of succinate to the medium until a concentration of 10 mcM is reached.
EFFECT: invention improves the efficiency of myogenesis of the C2C12 cell line.
1 cl, 2 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ACTIVATING THE MYOGENIC DIFFERENTIATION OF MYOBLASTS | 2021 |
|
RU2780589C1 |
| COMPOSITIONS OUT OF CULTURED MEAT | 2018 |
|
RU2778255C2 |
| METHOD FOR INCREASING BREAST CANCER RESISTANCE PROTEIN AMOUNT IN EXPERIMENT ON HUMAN HEPATOCELLULAR CARCINOMA CELL LINE | 2023 |
|
RU2803336C1 |
| METHOD OF OBTAINING POPULATION OF NEURAL DIFFERENTIATION INDUCED STROMAL CELLS OF FAT TISSUE | 2008 |
|
RU2396345C1 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| HOMO SAPIENS/MUS MUSCULUS 1B9C7 HYBRID CULTURED CELL STRAIN: PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE PROTEOLYTIC DOMAIN OF BOTULINUM TYPE A TOXIN | 2021 |
|
RU2783897C1 |
| STRAIN OF HYBRID CELLS OF ANIMALS Mus musculus 3F11 - PRODUCER OF MONOCLONAL ANTIBODIES SPECIFIC TO BOTULINUS TOXIN TYPE B | 2014 |
|
RU2566553C1 |
| STRAIN OF HYBRID ANIMAL CELLS Mus musculus 1G7 - PRODUCER OF MONOCLONAL ANTIBODIES SPECIFIC FOR BOTULINUM TOXIN OF TYPE B | 2014 |
|
RU2571208C1 |
| STRAIN OF HYBRID ANIMAL CELLS MUS MUSCULUS 2E1B5 - PRODUCER OF A MONOCLONAL ANTIBODY AGAINST THE RECEPROT-BINDING DOMAIN OF PROTEIN S OF THE SARS-CoV-2 VIRUS | 2021 |
|
RU2771288C1 |
| CELL PRODUCT OF INSULIN-PRODUCING MAMMALIAN CELLS AND USE THEREOF FOR DIABETES MELLITUS THERAPY | 2017 |
|
RU2663118C1 |
